期刊
AUTOIMMUNITY REVIEWS
卷 21, 期 1, 页码 -出版社
ELSEVIER
DOI: 10.1016/j.autrev.2021.102923
关键词
Cryoglobulinemic vasculitis; Mixed cryoglobulinemia; Hepatitis C virus; Outcome; Predictor; Severity index
类别
资金
- Ministry of Education, University and Research (Italy) Excellence Departments
- Ministry of Health [18RFAZ]
- Ricerca Finalizzata [18RFAZ]
This study provides a detailed analysis of CV patients treated with DAA-based regimes and followed-up for more than 72 weeks. It identifies clinical and laboratory predictors of disease outcome and proposes two new scores, CV and Global Severity Index, as reliable tools for predicting CV clinical response. These findings can fill a gap in the clinical management of HCV-related CV.
Cryoglobulinemic vasculitis (CV) is the most frequent extrahepatic manifestation during HCV-chronic infection. An effective Direct Acting Antiviral-treatment leads to CV clinical response in the majority of CV-patients although symptoms may persist/recur despite a sustained virological response. At present, no standardized clinical predictive factors for disease maintenance/recurrence were proposed, as emerged from a complete literature review we performed and reported. Here we provided a detailed descriptive analysis of a wide population of CV patients treated with DAA-based regimes and followed-up after therapy completion for longer than 72 weeks, in order to identify clinical or laboratory predictors of disease outcome and to optimize the patient management. Together with some baseline symptoms (neuropathy, weakness and sicca syndrome), two newly created scores, CV- and Global Severity Index, emerged as reliable and standardized tools to predict CV clinical response before initiating an antiviral therapy. In addition to predictive parameters previously proposed in the world literature, these novel Indexes could fill an unmet gap in the clinical management of the complex HCV-related CV.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据